|
Gene: STOM |
Gene summary for STOM |
Gene summary. |
Gene information | Species | Human | Gene symbol | STOM | Gene ID | 2040 |
Gene name | stomatin | |
Gene Alias | BND7 | |
Cytomap | 9q33.2 | |
Gene Type | protein-coding | GO ID | GO:0002028 | UniProtAcc | F8VSL7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2040 | STOM | LZE4T | Human | Esophagus | ESCC | 1.97e-14 | 7.94e-01 | 0.0811 |
2040 | STOM | LZE5T | Human | Esophagus | ESCC | 2.18e-04 | 1.82e-01 | 0.0514 |
2040 | STOM | LZE7T | Human | Esophagus | ESCC | 1.44e-07 | -1.96e-01 | 0.0667 |
2040 | STOM | LZE20T | Human | Esophagus | ESCC | 1.04e-09 | 8.52e-01 | 0.0662 |
2040 | STOM | LZE21D1 | Human | Esophagus | HGIN | 6.35e-04 | -2.51e-01 | 0.0632 |
2040 | STOM | LZE24D1 | Human | Esophagus | HGIN | 7.12e-08 | 3.34e-01 | 0.054 |
2040 | STOM | LZE24T | Human | Esophagus | ESCC | 2.51e-14 | 9.76e-01 | 0.0596 |
2040 | STOM | P2T-E | Human | Esophagus | ESCC | 1.46e-07 | 3.13e-01 | 0.1177 |
2040 | STOM | P4T-E | Human | Esophagus | ESCC | 9.71e-14 | 3.77e-01 | 0.1323 |
2040 | STOM | P5T-E | Human | Esophagus | ESCC | 1.40e-20 | 6.42e-01 | 0.1327 |
2040 | STOM | P9T-E | Human | Esophagus | ESCC | 9.62e-12 | 6.69e-01 | 0.1131 |
2040 | STOM | P10T-E | Human | Esophagus | ESCC | 2.46e-07 | -4.44e-01 | 0.116 |
2040 | STOM | P11T-E | Human | Esophagus | ESCC | 4.60e-06 | 6.64e-01 | 0.1426 |
2040 | STOM | P12T-E | Human | Esophagus | ESCC | 1.18e-47 | 1.55e+00 | 0.1122 |
2040 | STOM | P15T-E | Human | Esophagus | ESCC | 3.20e-37 | 1.26e+00 | 0.1149 |
2040 | STOM | P16T-E | Human | Esophagus | ESCC | 7.80e-16 | -2.68e-01 | 0.1153 |
2040 | STOM | P17T-E | Human | Esophagus | ESCC | 5.67e-03 | 6.19e-01 | 0.1278 |
2040 | STOM | P19T-E | Human | Esophagus | ESCC | 4.81e-03 | 1.23e+00 | 0.1662 |
2040 | STOM | P20T-E | Human | Esophagus | ESCC | 1.68e-16 | 7.22e-01 | 0.1124 |
2040 | STOM | P21T-E | Human | Esophagus | ESCC | 1.46e-28 | 1.06e+00 | 0.1617 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00453331 | Colorectum | SER | cellular respiration | 103/2897 | 230/18723 | 2.35e-26 | 3.61e-23 | 103 |
GO:00060911 | Colorectum | SER | generation of precursor metabolites and energy | 168/2897 | 490/18723 | 1.39e-25 | 1.70e-22 | 168 |
GO:00061191 | Colorectum | SER | oxidative phosphorylation | 75/2897 | 141/18723 | 2.35e-25 | 2.40e-22 | 75 |
GO:00159801 | Colorectum | SER | energy derivation by oxidation of organic compounds | 119/2897 | 318/18723 | 5.28e-22 | 4.62e-19 | 119 |
GO:00068391 | Colorectum | SER | mitochondrial transport | 87/2897 | 254/18723 | 7.91e-14 | 3.03e-11 | 87 |
GO:19026001 | Colorectum | SER | proton transmembrane transport | 60/2897 | 157/18723 | 3.12e-12 | 7.08e-10 | 60 |
GO:19905421 | Colorectum | SER | mitochondrial transmembrane transport | 42/2897 | 102/18723 | 3.65e-10 | 4.77e-08 | 42 |
GO:00061631 | Colorectum | SER | purine nucleotide metabolic process | 109/2897 | 396/18723 | 4.26e-10 | 5.44e-08 | 109 |
GO:00091501 | Colorectum | SER | purine ribonucleotide metabolic process | 103/2897 | 368/18723 | 4.69e-10 | 5.68e-08 | 103 |
GO:00725211 | Colorectum | SER | purine-containing compound metabolic process | 113/2897 | 416/18723 | 4.80e-10 | 5.68e-08 | 113 |
GO:00091441 | Colorectum | SER | purine nucleoside triphosphate metabolic process | 38/2897 | 88/18723 | 4.82e-10 | 5.68e-08 | 38 |
GO:00092591 | Colorectum | SER | ribonucleotide metabolic process | 104/2897 | 385/18723 | 3.27e-09 | 3.04e-07 | 104 |
GO:00091451 | Colorectum | SER | purine nucleoside triphosphate biosynthetic process | 31/2897 | 69/18723 | 5.91e-09 | 5.25e-07 | 31 |
GO:00196931 | Colorectum | SER | ribose phosphate metabolic process | 105/2897 | 396/18723 | 8.15e-09 | 7.14e-07 | 105 |
GO:00159851 | Colorectum | SER | energy coupled proton transport, down electrochemical gradient | 17/2897 | 26/18723 | 1.22e-08 | 9.74e-07 | 17 |
GO:00159861 | Colorectum | SER | ATP synthesis coupled proton transport | 17/2897 | 26/18723 | 1.22e-08 | 9.74e-07 | 17 |
GO:00092051 | Colorectum | SER | purine ribonucleoside triphosphate metabolic process | 34/2897 | 82/18723 | 1.37e-08 | 1.05e-06 | 34 |
GO:00067541 | Colorectum | SER | ATP biosynthetic process | 27/2897 | 57/18723 | 1.38e-08 | 1.05e-06 | 27 |
GO:00092061 | Colorectum | SER | purine ribonucleoside triphosphate biosynthetic process | 30/2897 | 68/18723 | 1.74e-08 | 1.28e-06 | 30 |
GO:00427761 | Colorectum | SER | mitochondrial ATP synthesis coupled proton transport | 14/2897 | 19/18723 | 2.35e-08 | 1.68e-06 | 14 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STOM | SNV | Missense_Mutation | c.863N>C | p.Gly288Ala | p.G288A | P27105 | protein_coding | tolerated(0.18) | benign(0) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
STOM | SNV | Missense_Mutation | novel | c.545N>T | p.Thr182Ile | p.T182I | P27105 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STOM | SNV | Missense_Mutation | rs747153047 | c.295N>G | p.Ile99Val | p.I99V | P27105 | protein_coding | tolerated(1) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STOM | SNV | Missense_Mutation | novel | c.428N>A | p.Thr143Asn | p.T143N | P27105 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-IR-A3L7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STOM | SNV | Missense_Mutation | c.431N>A | p.Arg144His | p.R144H | P27105 | protein_coding | tolerated(0.09) | benign(0.168) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STOM | SNV | Missense_Mutation | rs763192503 | c.572N>A | p.Arg191His | p.R191H | P27105 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-NH-A50T-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STOM | SNV | Missense_Mutation | rs201671242 | c.673N>A | p.Glu225Lys | p.E225K | P27105 | protein_coding | deleterious(0.02) | possibly_damaging(0.617) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
STOM | SNV | Missense_Mutation | rs867557202 | c.299N>T | p.Ser100Leu | p.S100L | P27105 | protein_coding | deleterious(0) | possibly_damaging(0.672) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
STOM | SNV | Missense_Mutation | novel | c.857N>G | p.His286Arg | p.H286R | P27105 | protein_coding | tolerated(0.17) | benign(0.003) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
STOM | SNV | Missense_Mutation | novel | c.752N>A | p.Arg251Gln | p.R251Q | P27105 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |